- DTG/FTC/TAF is comprised of Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg - - Mylan's DTG/FTC/TAF will be the first TAF-based fixed-dose combination to be offered to patients in developing countries being treated for HIV - HERTFORDSHIRE, England
HERTFORDSHIRE, England , and PITTSBURGH , Feb. 8, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will release its fourth quarter and full year 2017 financial results, as well as its 2018 financial guidance, on Wednesday, Feb. 28 , following the close of the U.S.
BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH and SAO PAULO , Dec. 29, 2017 /PRNewswire/ -- Biosimilar Trastuzumab, co-developed by Biocon Ltd. (BSE code: 532523, NSE: BIOCON ) and Mylan N.V. (NASDAQ, TASE: MYL), has been approved by ANVISA, the Brazilian regulatory agency, through
HERTFORDSHIRE, England and PITTSBURGH , Dec. 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its CEO, Heather Bresch , will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. , on Tuesday, Jan. 9, 2018 , at 3 p.m. PT ( 6 p.m. ET ).